Galantamine for Cognition in People With Schizophrenia
Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
This study is a double-blind, placebo-controlled trial of the nicotinic receptor agonist,
galantamine, for the improvement of memory and attention in people with schizophrenia and
schizoaffective disorder. Twenty subjects on a stable dose of antipsychotic medications
receive galantamine or identical placebo tablets for 8 weeks. Adverse events are screened for
every week. Tests of memory, attention, and reward responsivity are performed at baseline and
afer 8 weeks on medication. Clinical scales rating psychiatric symptoms are performed at the
beginning, middle, and end of the trial.